TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04025372
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bicalutamide is categorized as an antiandrogen. Antiandrogens are substances that block the effects of testosterone. Cancer of the prostate depends on the male hormone testosterone for its growth. If the amount of testosterone is reduced it is possible to slow down or shrink the cancer.
Study: NCT04025372
Drug: GnRH Agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In men, GnRH agonists cause the testicles to stop making testosterone. Some GnRH agonists are used to treat prostate cancer.
Study: NCT00020657
Drug: dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020657
Drug: granisetron hydrochloride
Normalized name: Granisetron Hydrochloride
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01791387
Drug: Dovitinib
Normalized name: Dovitinib
DrugBank: Dovitinib (DB05928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.~If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions.
Study: NCT00201643
Drug: Betamethasone or Dexamethasone (2nd course of ACS)
Normalized name: Dexamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Course of Betamethasone or Dexamethasone
Study: NCT00020657
Drug: ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020657
Drug: prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00193375
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg/m2 days 1 \& 8 each 21-day cycle 1 \& 2, 28-day cycle 3 \& 4
Study: NCT00193375
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5
Study: NCT00193375
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10mg/kg IV every 2 weeks for 10 doses starting week 16
Study: NCT02611336
Drug: Tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil 20 mg to be taken orally once daily, for 3 months
Study: NCT02187159
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 150 mg capsule for oral administration
Study: NCT03641508
Drug: Triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide (Kenalog; 10 mg/mL; insoluble). This will be mixed with 1% lidocaine without epinephrine
Study: NCT00171041
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03641508
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexamethasone sodium phosphate (Decadron; 4 mg/mL; soluble). Again, this will be mixed with 1% lidocaine without epinephrine
Study: NCT04107168
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human immunoglobulin G4 (IgG4) monoclonal antibody, which binds to the programmed death-1 receptor (PD-1).
Study: NCT04107168
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human immunoglobulin G4-kappa (IgG4-kappa) monoclonal antibody that targets PD-1.
Study: NCT02473185
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cross-over
Study: NCT04025372
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide belongs to a class of drugs called androgen receptor inhibitors. In the body, these agents compete with androgens for binding to the androgen receptor, which reduces the ability of androgens to promote the growth of prostate cancer cells
Study: NCT04107168
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human immunoglobulin G1 (IgG1) monoclonal antibody raised against cytotoxic T lymphocyte antigen-4 (CTLA-4).
Study: NCT04107168
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A human immunoglobulin G1-kappa (IgG1-kappa) monoclonal antibody that binds to programmed death ligand 1 (PD-L1).
Study: NCT04107168
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fully human monoclonal antibody raised to target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4).
Study: NCT04107168
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A humanised IgG1 monoclonal antibody raised to target programmed death-ligand 1 (PD-L1).
Study: NCT04107168
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A humanised IgG1 monoclonal antibody raised to target vascular endothelial growth factor (VEGF).
Study: NCT03207451
Drug: Vorapaxar
Normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vorapaxar is the principle study drug and will be given to all subjects.
Study: NCT03207451
Drug: Vorapaxar and Aspirin
DrugBank: Vorapaxar (DB09030)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
Study: NCT03207451
Drug: Vorapaxar and Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
Study: NCT03207451
Drug: Vorapaxar, Aspirin, and Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
Study: NCT03552705
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
Study: NCT01064271
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Risperidone Tablets 1 mg
Study: NCT02672098
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.~a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C).
Study: NCT01149655
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Study: NCT01149655
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Study: NCT03308669
Drug: Lasmiditan
Normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT03308669
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT00296751
Drug: Intravenous meperidine injection
Normalized name: meperidine Injection
DrugBank: Meperidine (DB00454)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00296751
Drug: Epidural Bupivacaine and fentanyl injection
Normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04288219
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine 30mg, Pharmacotherapy
Study: NCT04504916
Drug: Zilovertamab vedotin
Normalized name: Zilovertamab vedotin
DrugBank: Zilovertamab vedotin (DB18457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT01366664
Drug: Treatment sequence 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
Study: NCT04594759
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be getting isotretinoin (1-1.5 mg/kg/week)
Study: NCT00311363
Drug: GEn (XP13512)
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
Study: NCT00311363
Drug: GEn (XP13512)
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
Study: NCT00396084
Drug: Gatifloxacin
Normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg/day x 7 days.
Study: NCT00396084
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 300 mg/day x 7 days.
Study: NCT00396084
Drug: Levofloxacin
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin 1000 mg/day x 7 days.
Study: NCT00396084
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
Study: NCT00396084
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg/day x 7 days.
Study: NCT02885324
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive Cabozantinib
Study: NCT04365023
Drug: platinum chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line platinum chemotherapy
Study: NCT01470001
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patient will receive solifenacin 5mg daily or placebo daily
Study: NCT02974933
Drug: Apatinib combined with pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
Study: NCT00492518
Drug: Acetylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03981536
Drug: AP-101
Normalized name: AP-101
DrugBank: AP-101 (DB17947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by intravenous infusion (IV)
Study: NCT04601740
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study: NCT00486005
Drug: Olanzapine Hydrochloride
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00486005
Drug: Nizatidine
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02904759
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02620813
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take isotretinoin as prescribed by their dermatologist.
Study: NCT01806116
Drug: decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00103558
Drug: Lumiliximab with FCR
Normalized name: Primatene with ephedrine Pill
DrugBank: Lumiliximab (DB06162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose, schedule, and duration specified in protocol
Study: NCT01140971
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
Study: NCT00863915
Drug: Ramipril10 mg Capsules, single dose
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
Study: NCT04355364
Drug: Dornase Alfa Inhalation Solution [Pulmozyme]
Normalized name: dornase alfa Inhalation Solution [Pulmozyme]
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
Study: NCT02564367
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks
Study: NCT03442725
Drug: Telotristat etiprate
Normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Study: NCT03638128
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution for injection
Study: NCT03638128
Drug: Alternative osteoporosis medications
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative osteoporosis medication/s at the discretion of the investigator.
Study: NCT01856738
Drug: Rivastigmine
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule. Dose 3,0 - 6,0 mg BID
Study: NCT05108766
Drug: Tildrakizumab 100 mg
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
Study: NCT00944918
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
Study: NCT00944918
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, once daily until disease progression.
Study: NCT02672722
Drug: Definity
Normalized name: Definity
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
Study: NCT03316521
Drug: AMY-101
Normalized name: AMY-101
DrugBank: AMY-101 (DB14803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
Study: NCT00944918
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, oral, once daily until disease progression.
Study: NCT02743975
Drug: Bevacizumab-800CW
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dose finding: 4.5mg; 10mg; 25mg; 50mg
Study: NCT03038516
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
Study: NCT00151333
Drug: SRA-333
Normalized name: SRA-737
DrugBank: SRA-737 (DB16876)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01535677
Drug: Dapagliflozin + Glucophage tablet fasted
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
Study: NCT01535677
Drug: Dapagliflozin/metformin IR FDC tablet fasted
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
Study: NCT01535677
Drug: Dapagliflozin + Glucophage tablet fed
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
Study: NCT01535677
Drug: Dapagliflozin/metformin IR FDC tablet fed
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
Study: NCT00680329
Drug: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: One drop in study eye(s) once daily in the evening for four months
Study: NCT03339583
Drug: Zopiclone
Normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
Study: NCT00699049
Drug: solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT02934256
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
Study: NCT03347097
Drug: TIL
Normalized name: Tilia
DrugBank: Tilia americana pollen (DB10732)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03347097
Drug: PD1-TIL
Normalized name: CD8 enriched young TIL
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00234845
Drug: adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03519906
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are tested for their normal prescription metaprolol medication
Study: NCT03591861
Drug: BCNU
Normalized name: BCNU
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: -Standard of care
Study: NCT00335647
Drug: fluphenazine hydrochloride
Normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02757040
Drug: Ibrutinib combined with As2O3
Normalized name: Ibrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: arsenic trioxide combined with ibrutinib in CLL
Study: NCT02757040
Drug: ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ibrutinib
Study: NCT00958503
Drug: Thiamphenicol
Normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 and 1500 mg/day;tablets
Study: NCT01353859
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg/kg iv every 4 weeks for a total of 6 infusions
Study: NCT03909529
Drug: Digoxin 250 MCG Oral Tablet
Normalized name: digoxin 250 MCG Oral Tablet
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Study: NCT02233218
Drug: Telmisartan
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02233218
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04545801
Drug: 0.25 mg/kg of Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
Study: NCT01631227
Drug: Eprosartan
Normalized name: Eprosartan
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eprosartan 450 mg
Study: NCT01631227
Drug: Eprosartan Mesylate
Normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eprosartan mesylate 600 mg
Study: NCT01631227
Drug: Placebo Eprosartan mesylate
Normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo Eprosartan mesylate